ViiV Healthcare

ViiV Healthcare is a specialist pharmaceutical company dedicated to the research, development, and commercialisation of medicines for HIV treatment and prevention.

Its portfolio includes widely used antiretroviral therapies such as Dovato and the long-acting injectable Cabenuva, and it is advancing next-generation approaches including long-acting prevention with Apretude.

ViiV is a joint venture majority-owned by GSK, with Pfizer and Shionogi as minority shareholders, and holds approximately 32% of the global HIV therapy market.